Search

Your search keyword '"Nurmohamed, Michael T"' showing total 855 results
Start Over Author "Nurmohamed, Michael T"
855 results on '"Nurmohamed, Michael T"'

202. Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?

Author

Konijn, Nicole P. C., primary, van Tuyl, Lilian H. D., additional, Boers, Maarten, additional, den Uyl, Debby, additional, ter Wee, Marieke M., additional, Kerstens, Pit, additional, Voskuyl, Alexandre E., additional, van Schaardenburg, Dirkjan, additional, Nurmohamed, Michael T., additional, and Lems, Willem F., additional

Published
2017
Full Text
View/download PDF

205. Brief Report: The Role of Rare Protein‐Coding Variants in Anti–Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis

Author

Cui, Jing, primary, Diogo, Dorothee, additional, Stahl, Eli A., additional, Canhao, Helena, additional, Mariette, Xavier, additional, Greenberg, Jeffrey D., additional, Okada, Yukinori, additional, Pappas, Dimitrios A., additional, Fulton, Robert S., additional, Tak, Paul P., additional, Nurmohamed, Michael T., additional, Lee, Annette, additional, Larson, David E., additional, Kurreeman, Fina, additional, Deluca, Tracie L., additional, O'Laughlin, Michelle, additional, Fronick, Catrina C., additional, Fulton, Lucinda L., additional, Mardis, Elaine R., additional, van der Horst‐Bruinsma, Irene E., additional, Wolbink, Gert‐Jan, additional, Gregersen, Peter K., additional, Kremer, Joel M., additional, Crusius, J. Bart A., additional, de Vries, Niek, additional, Huizinga, Tom W. J., additional, Fonseca, João Eurico, additional, Miceli‐Richard, Corinne, additional, Karlson, Elizabeth W., additional, Coenen, Marieke J. H., additional, Barton, Anne, additional, Plenge, Robert M., additional, and Raychaudhuri, Soumya, additional

Published
2017
Full Text
View/download PDF

208. TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits

Author

Diogo, Dorothée, Bastarache, Lisa, Liao, Katherine P., Graham, Robert R., Fulton, Robert S., Greenberg, Jeffrey D., Eyre, Steve, Bowes, John, Cui, Jing, Lee, Annette, Pappas, Dimitrios A., Kremer, Joel M., Barton, Anne, Coenen, Marieke J. H., Franke, Barbara, Kiemeney, Lambertus A., Mariette, Xavier, Richard-Miceli, Corrine, Canhão, Helena, Fonseca, João E., De Vries, Niek, P. Tak, Paul, Crusius, J. Bart A., Nurmohamed, Michael T., Kurreeman, Fina, Mikuls, Ted R., Okada, Yukinori, Stahl, Eli A., Larson, David E., Deluca, Tracie L., O'Laughlin, Michelle, Fronick, Catrina C., Fulton, Lucinda L., Kosoy, Roman, Ransom, Michael, Bhangale, Tushar R., Ortmann, Ward, Cagan, Andrew, Gainer, Vivian, Karlson, Elizabeth W., Kohane, Isaac, Murphy, Shawn N., Martin, Javier, Zhernakova, Alexandra, Klareskog, Lars, Padyukov, Leonid, Worthington, Jane, Mardis, Elaine R., Seldin, Michael F., Gregersen, Peter K., Behrens, Timothy, Raychaudhuri, Soumya, Denny, Joshua C., Plenge, Robert M., and Columbia University. Medicine

Subjects
Systemic lupus erythematosus, Phenotype, Autoimmune diseases--Treatment, Rheumatoid arthritis--Treatment, FOS: Biological sciences, FOS: Clinical medicine, Immunology, Genetics, Medicine, Inflammatory bowel diseases, Protein-tyrosine kinase
Abstract

Despite the success of genome-wide association studies (GWAS) in detecting a large number of loci for complex phenotypes such as rheumatoid arthritis (RA) susceptibility, the lack of information on the causal genes leaves important challenges to interpret GWAS results in the context of the disease biology. Here, we genetically fine-map the RA risk locus at 19p13 to define causal variants, and explore the pleiotropic effects of these same variants in other complex traits. First, we combined Immunochip dense genotyping (n = 23,092 case/control samples), Exomechip genotyping (n = 18,409 case/control samples) and targeted exon-sequencing (n = 2,236 case/controls samples) to demonstrate that three protein-coding variants in TYK2 (tyrosine kinase 2) independently protect against RA: P1104A (rs34536443, OR = 0.66, P = 2.3x10-21), A928V (rs35018800, OR = 0.53, P = 1.2x10-9), and I684S (rs12720356, OR = 0.86, P = 4.6x10-7). Second, we show that the same three TYK2 variants protect against systemic lupus erythematosus (SLE, Pomnibus = 6x10-18), and provide suggestive evidence that two of the TYK2 variants (P1104A and A928V) may also protect against inflammatory bowel disease (IBD; Pomnibus = 0.005). Finally, in a phenomewide association study (PheWAS) assessing >500 phenotypes using electronic medical records (EMR) in >29,000 subjects, we found no convincing evidence for association of P1104A and A928V with complex phenotypes other than autoimmune diseases such as RA, SLE and IBD. Together, our results demonstrate the role of TYK2 in the pathogenesis of RA, SLE and IBD, and provide supporting evidence for TYK2 as a promising drug target for the treatment of autoimmune diseases.

Published
2015
Full Text
View/download PDF

210. Erratum to: Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study

Author

Bernelot Moens, Sophie J., primary, van der Valk, Fleur M., additional, Strang, Aart C., additional, Kroon, Jeffrey, additional, Smits, Loek P., additional, Kneepkens, Eva L., additional, Verberne, Hein J., additional, van Buul, Jaap D., additional, Nurmohamed, Michael T., additional, and Stroes, Erik S. G., additional

Published
2016
Full Text
View/download PDF

213. The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis

Author

Konijn, Nicole P. C., primary, van Tuyl, Lilian H. D., additional, Boers, Maarten, additional, van de Ven, Peter M., additional, den Uyl, Debby, additional, ter Wee, Marieke M., additional, Kerstens, Pit, additional, Voskuyl, Alexandre E., additional, van Schaardenburg, Dirkjan, additional, Lems, Willem F., additional, and Nurmohamed, Michael T., additional

Published
2016
Full Text
View/download PDF

214. Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study

Author

Bernelot Moens, Sophie J., primary, van der Valk, Fleur M., additional, Strang, Aart C., additional, Kroon, Jeffrey, additional, Smits, Loek P., additional, Kneepkens, Eva L., additional, Verberne, Hein J., additional, van Buul, Jaap D., additional, Nurmohamed, Michael T., additional, and Stroes, Erik S. G., additional

Published
2016
Full Text
View/download PDF

217. Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study

Author

Alten, Rieke, primary, Nüßlein, Hubert, additional, Galeazzi, Mauro, additional, Lorenz, Hanns-Martin, additional, Nurmohamed, Michael T, additional, Bensen, William G, additional, Burmester, Gerd R, additional, Peter, Hans-Hartmut, additional, Pavelka, Karel, additional, Chartier, Mélanie, additional, Poncet, Coralie, additional, Rauch, Christiane, additional, Elbez, Yedid, additional, and Le Bars, Manuela, additional

Published
2016
Full Text
View/download PDF

218. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.

Author

l'Ami, Merel J., Krieckaert, Charlotte L. M., Nurmohamed, Michael T., van Vollenhoven, Ronald F., Rispens, Theo, Boers, Maarten, Wolbink, Gerrit Jan, and Krieckaert, Charlotte Lm

Subjects
ANTIRHEUMATIC agents, COMPARATIVE studies, DRUG administration, DOSE-effect relationship in pharmacology, RESEARCH methodology, MEDICAL cooperation, RESEARCH, RHEUMATOID arthritis, STATISTICAL sampling, EVALUATION research, RANDOMIZED controlled trials, TREATMENT effectiveness, SEVERITY of illness index
Abstract

Objective: High adalimumab serum concentrations do not result in better response in patients with rheumatoid arthritis (RA), suggesting overexposure. We investigated whether patients with adalimumab concentrations >8 µg/mL can prolong their dosing interval by 50% without a clinically relevant change in disease activity.Methods: Consecutive patients with RA, treated with adalimumab 40 mg every other week for at least 28 weeks, were approached for this randomised, open-label, non-inferiority trial. Patients with adalimumab trough concentrations >8 µg/mL were randomly (1:1) assigned to dose-interval prolongation of once every 3 weeks or continuation of every other week. Primary outcome was the change in disease activity score of 28 joints (ΔDAS28-ESR) after 28 weeks, with a non-inferiority margin of 0.6 points.Results: In total, 147 patients were screened. Fifty-five patients had concentrations >8 µg/mL and were randomised. Mean ΔDAS28 after 28 weeks was -0.14±SD 0.61 in the prolongation group and 0.30±0.52 in the continuation group. Mean difference was significantly in favour of the prolongation group: 0.44 (95% CI 0.12 to 0.76, p=0.01).Conclusions: Adalimumab-treated patients with RA with trough concentrations >8 µg/mL can prolong their standard dosing interval to once every 3 weeks without loss of disease control.Trial Registration Number: NTR3509; Results. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

221. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study

Author

Nüßlein, Hubert G., primary, Alten, Rieke, additional, Galeazzi, Mauro, additional, Lorenz, Hanns-Martin, additional, Nurmohamed, Michael T., additional, Bensen, William G., additional, Burmester, Gerd R., additional, Peter, Hans-Hartmut, additional, Pavelka, Karel, additional, Chartier, Melanie, additional, Poncet, Coralie, additional, Rauch, Christiane, additional, and Le Bars, Manuela, additional

Published
2015
Full Text
View/download PDF

223. TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits

Author

Diogo, Dorothée, primary, Bastarache, Lisa, additional, Liao, Katherine P., additional, Graham, Robert R., additional, Fulton, Robert S., additional, Greenberg, Jeffrey D., additional, Eyre, Steve, additional, Bowes, John, additional, Cui, Jing, additional, Lee, Annette, additional, Pappas, Dimitrios A., additional, Kremer, Joel M., additional, Barton, Anne, additional, Coenen, Marieke J. H., additional, Franke, Barbara, additional, Kiemeney, Lambertus A., additional, Mariette, Xavier, additional, Richard-Miceli, Corrine, additional, Canhão, Helena, additional, Fonseca, João E., additional, de Vries, Niek, additional, Tak, Paul P., additional, Crusius, J. Bart A., additional, Nurmohamed, Michael T., additional, Kurreeman, Fina, additional, Mikuls, Ted R., additional, Okada, Yukinori, additional, Stahl, Eli A., additional, Larson, David E., additional, Deluca, Tracie L., additional, O'Laughlin, Michelle, additional, Fronick, Catrina C., additional, Fulton, Lucinda L., additional, Kosoy, Roman, additional, Ransom, Michael, additional, Bhangale, Tushar R., additional, Ortmann, Ward, additional, Cagan, Andrew, additional, Gainer, Vivian, additional, Karlson, Elizabeth W., additional, Kohane, Isaac, additional, Murphy, Shawn N., additional, Martin, Javier, additional, Zhernakova, Alexandra, additional, Klareskog, Lars, additional, Padyukov, Leonid, additional, Worthington, Jane, additional, Mardis, Elaine R., additional, Seldin, Michael F., additional, Gregersen, Peter K., additional, Behrens, Timothy, additional, Raychaudhuri, Soumya, additional, Denny, Joshua C., additional, and Plenge, Robert M., additional

Published
2015
Full Text
View/download PDF

227. List of Contributors

Author

Agostini, Carlo, Alunno, Alessia, Ayvazyan, Lilit, Barbosa-Ferreira, João Marcos, Bartoloni, Elena, Binder, Christoph J., Bornholz, Beatrice, Braun, Jürgen, Brucato, Antonio, Buyon, Jill P., Caforio, Alida L.P., Dennert, Robert, Diederichsen, Louise Pyndt, Dimitroulas, Theodoros, Dörr, Marcus, Felix, Stephan B., Fernandes, Fabio, Fragkioudaki, Sofia, Freschi de Barros, Samar, Friedman, Deborah M., Gallo, Nicoletta, Gasparyan, Armen Yuri, Gerli, Roberto, Gruber, Sabrina, Guilherme, Luiza, Guillevin, Loïc, Hazebroek, Mark, Heslinga, Sjoerd C., Heymans, Stephane, Iliceto, Sabino, Imazio, Massimo, Jiang, Xiongjing, Kalil, Jorge, Kitas, George D., Köhler, Karen Francine, Könemann, Stephanie, Koster, Matthew J., Landewé, Robert, Livneh, Avi, Lundberg, Ingrid E., Maestroni, Silvia, Malik, Marek, Malipiero, Giacomo, Marcolongo, Renzo, Martini, Alberto, Matteson, Eric L., Mavragani, Clio P., Metsios, George S., Miliaresis, Christa, Mithal, Leena B., Moutsopoulos, Haralampos M., Müller, Johannes, Nurmohamed, Michael T., Nussinovitch, U., Sullivan, Miriam O’, Phoon, Colin K.L., Pipitone, Nicolò, Plebani, Mario, Pucci, Giacomo, Ramoni, Veronique, Ravelli, Angelo, Reuter, Caroline, Roggenbuck, Dirk, Rose, Noel R., Russell, Stuart D., Sabino, Ester Cerdeira, Salvarani, Carlo, Sampaio, Roney Orismar, Sandoo, Aamer, Sanner, Helga, Schiappapietra, Benedetta, Schillaci, Giuseppe, Schimke, Ingolf, Seguso, Mara, Shamriz, Oded, Shulman, Stanford T., Sjaastad, Ivar, Skeoch, Sarah, Soriano, Alessandra, Guilherme, Sobreira Spina, Tarasoutchi, Flavio, Trappe, Hans-Joachim, Tselios, Konstantinos, Tsiantoulas, Dimitrios, Urowitz, Murray B., Vacca, Alessandra, Valente Moreira, Carlos Henrique, Valenti, Anna, van Durme, Caroline, van Paassen, Pieter, Verazza, Sara, Wallukat, Gerd, Warrington, Kenneth J., Yang, Lirui, Yessirkepov, Marlen, and Zhang, Huimin

Published
2017
Full Text
View/download PDF

229. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study

Author

van Halm, Vokko P, Nurmohamed, Michael T, Twisk, Jos W R, Dijkmans, Ben A C, Voskuyl, Alexandre E, Cardiology, Internal medicine, Epidemiology and Data Science, and Rheumatology

Abstract

Rheumatoid arthritis (RA) is characterized by inflammation and an increased risk for cardiovascular disease (CVD). This study investigates possible associations between CVD and the use of conventional disease-modifying antirheumatic drugs (DMARDs) in RA. Using a case control design, 613 RA patients (5,649 patient-years) were studied, 72 with CVD and 541 without CVD. Data on RA, CVD and drug treatment were evaluated from time of RA diagnosis up to the first cardiovascular event or the end of the follow-up period. The dataset was categorized according to DMARD use: sulfasalazine (SSZ), hydroxychloroquine (HCQ) or methotrexate (MTX). Odds ratios (ORs) for CVD, corrected for age, gender, smoking and RA duration, were calculated per DMARD group. Patients who never used SSZ, HCQ or MTX were used as a reference group. MTX treatment was associated with a significant CVD risk reduction, with ORs (95% CI): 'MTX only', 0.16 (0.04 to 0.66); 'MTX and SSZ ever', 0.20 (0.08 to 0.51); and 'MTX, SSZ and HCQ ever', 0.20 (0.08 to 0.54). The risk reductions remained significant after additional correction for the presence of rheumatoid factor and erosions. After correction for hypertension, diabetes and hypercholesterolemia, 'MTX or SSZ ever' and 'MTX, SSZ and HCQ ever' showed significant CVD risk reduction. Rheumatoid factor positivity and erosions both increased CVD risk, with ORs of 2.04 (1.02 to 4.07) and 2.36 (0.92 to 6.08), respectively. MTX and, to a lesser extent, SSZ were associated with significantly lower CVD risk compared to RA patients who never used SSZ, HCQ or MTX. We hypothesize that DMARD use, in particular MTX use, results in powerful suppression of inflammation, thereby reducing the development of atherosclerosis and subsequently clinically overt CVD.

Published
2006
Full Text
View/download PDF

230. Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases.

Author

Kneepkens, Eva L., Pouw, Mieke F., Wolbink, Gerrit Jan, Schaap, Tiny, Nurmohamed, Michael T., Vries, Annick, Rispens, Theo, and Bloem, Karien

Subjects
ADALIMUMAB, DRUG monitoring, DRIED blood spot testing, VENOUS puncture, RHEUMATISM treatment, IMMUNOGLOBULINS, THERAPEUTICS
Abstract

Aims Development of a self-sampling method for therapeutic drug monitoring (TDM) of biologicals will enhance TDM implementation in routine care and pharmacokinetic knowledge. The aim of this study was to compare adalimumab and anti-adalimumab antibody (ADA) concentration measurements in dried blood spots (DBS) obtained from finger prick with measurements in serum obtained via venepuncture, from patients with rheumatic inflammatory diseases. Methods In this cross-sectional study, 161 consecutive patients were included. For clinical validation, DBS from finger prick and serum from venepuncture were collected simultaneously and adalimumab and ADA concentration were assessed by ELISA and antigen binding test (ABT), respectively. To convert DBS eluate results to values which can be compared to serum concentrations, five different methods were investigated, using a marker protein or a volumetric approach. Results Adalimumab and ADA concentrations obtained from the finger prick/DBS method correlated well with serum results from the same patient (correlation coefficient > 0.87). Interestingly, antibody concentrations (either adalimumab, ADA or total immunoglobulin G) in DBS from finger prick, but not albumin, were systematically lower compared to serum. Spike experiments demonstrated a quantitative recovery for all tested proteins in DBS, suggesting a slightly different protein composition of blood collected via finger prick vs. venepuncture. We established a correction factor to relate finger prick/DBS values with serum values (approximately 1.2). Conclusions We show here for the first time that adalimumab and ADA serum concentrations can be satisfactorily estimated by measuring concentrations in DBS eluates, collected by finger prick. This method offers great opportunity to simplify TDM of adalimumab. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

232. Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.

Author

Konijn, Nicole P. C., van Tuyl, Lilian H. D., Boers, Maarten, den Uyl, Debby, ter Wee, Marieke M., van der Wijden, Lindsey K. M., Bultink, Irene E. M., Kerstens, Pit J. S. M., Voskuyl, Alexandre E., van Schaardenburg, Dirkjan, Nurmohamed, Michael T., and Lems, Willem F.

Subjects
ANTIRHEUMATIC agents, COMBINATION drug therapy, INTERVIEWING, MEDICAL needs assessment, METHOTREXATE, RESEARCH funding, RHEUMATOID arthritis, STATISTICAL sampling, COMORBIDITY, DATA analysis software, DESCRIPTIVE statistics, PREDNISOLONE
Abstract

Objective. To assess the efficacy and safety of initial COBRA-light vs COBRA therapy in RA patients after a 4-year follow-up period. Methods. In the COBRA-light trial, 162 consecutive patients with recent-onset RA were randomized to either COBRA-light (prednisolone and MTX) or COBRA therapy (prednisolone, MTX and SSZ) for 1 year. After 1 year, treatment was continued without protocol, and adjusted by the treating physician according to clinical judgement, preferably with a treat-to-target strategy. Four years after trial initiation, all patients were invited to participate in the COBRA-light extension study, in which patients were interviewed and physically examined, patient reported outcomes were assessed, radiographs were made and clinical records were examined for comorbidities and medication use. Results. In the extension study, 149 out of 162 (92%) original trial patients participated: 72 COBRA-light and 77 COBRA patients. Initial COBRA-light and COBRA therapy showed similar effect on disease activity, physical functioning, radiological outcome and Boolean remission over the 4-year follow-up period. In addition, both treatment groups showed similar survival and major comorbidities, although the power to detect differences was limited. Besides protocolled differences in prednisolone, MTX and SSZ use, the use of other synthetic and biologic DMARDs and intra-articular and intramuscular glucocorticoid injections was similar in both treatment groups over the 4-year period. Conclusion. Early RA patients initially treated with COBRA-light or COBRA therapy had similar efficacy and safety outcomes over a 4-year follow-up period. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

233. Muscle wasting in male TNF-α blocker naïve ankylosing spondylitis patients: a comparison of gender differences in body composition.

Author

Vodnizza, Sebastián Ibáñez, Visman, Ingrid M., van Denderen, Christiaan, Lems, Willem F., Jaime, Francisca, Nurmohamed, Michael T., and van der Horst-Bruinsma, Irene E.

Subjects
ANKYLOSING spondylitis, BODY composition, COMPARATIVE studies, RESEARCH funding, SEX distribution, DATA analysis software, WASTING syndrome, DESCRIPTIVE statistics
Abstract

Objective. To assess gender differences in body composition (BC) in a cohort of AS patients naïve to TNF-α blockers. Methods. Patients included fulfilled the Modified New York criteria for AS. Demographic information and disease activity measures (ASDAS and BASDAI) were reported. BC was measured by whole body DXA. Body fat percentage (BF%), fat mass index (FMI), fat free mass index (FFMI) and android/gynoid fat ratio were reported and compared between men and women and with the reference population (percentiles). Results. Seventy consecutive patients were included; 60% were men. Demographic variables were similar, except for dyslipidaemia (57.1% of men; 14.3% of women). Women had significantly more fat (BF%, FMI), and less muscle (FFMI) than men, but below the median of the reference population. Male AS patients had a markedly low FFMI (31.7th percentile) compared with the reference population. In the whole group, after multivariate analysis, an ASDAS CRP>3.5 was related to lower fat free mass content. In men, a significant relationship between having a high disease activity (ASDAS, BASDAI) and lower BF% or FMI percentile was found, but in women it was the opposite. Conclusion. Muscle wasting, measured as low FFMI compared with the reference population, was found in male TNF-α blocker naïve AS patients, especially in those with active disease. Women had higher volumes of body fat than men, but near the median of the reference population. The relationships between fat content and disease activity support the complex association between adipose tissue and inflammation. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

234. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis

Author

Vis, Marijn, Nurmohamed, Michael T, Wolbink, Gertjan, Voskuyl, Alexandre E, de Koning, Margret, van de Stadt, Rob, Twisk, Jos W R, Dijkmans, Ben A C, Lems, Willem F, Internal medicine, Epidemiology and Data Science, APH - Health Behaviors & Chronic Diseases, APH - Methodology, Rheumatology, AII - Inflammatory diseases, AMS - Musculoskeletal Health, and AMS - Tissue Function & Regeneration

Abstract

OBJECTIVE: Cardiovascular morbidity and mortality appear to be enhanced in rheumatoid arthritis (RA), which might be due to an increased prevalence of cardiovascular risk factors such as dyslipidemia. It was recently shown that effective disease modifying antirheumatic drug treatment had a favorable influence on the lipid profile in patients with active RA. As infliximab markedly reduces disease activity in RA, we investigated the effects of infliximab on the lipid profile.METHODS: Infliximab was administered at baseline and at 2 and 6 weeks in patients with active RA. Total cholesterol and HDL-cholesterol concentrations were measured and their ratio, the atherogenic index (an important cardiovascular risk factor indicator), was assessed.RESULTS: Sixty-nine patients were enrolled. The Disease Activity Index score (DAS-28) was 5.9 (SD +/- 1.4) at baseline and decreased to 4.6 (+/- 1.4) after 2 weeks and further to 4.1 (+/- 1.5) after 6 weeks. Total cholesterol level was 5.2 mmol/l at baseline and increased to 5.7 mmol/l (p < 0.001) at 2 weeks, and was 5.6 mmol/l (p < 0.001 vs baseline) at Week 6. For HDL-cholesterol these values were 1.5, 1.6 (p < 0.001), and 1.6 mmol/l (p < 0.001 vs baseline), respectively. Changes in disease activity were significantly inversely associated with changes in total cholesterol and HDL-cholesterol levels. The atherogenic index, however, remained constant. Corticosteroid use at baseline was associated with significantly higher total cholesterol and HDL-cholesterol levels and a lower (more favorable) atherogenic index at baseline.CONCLUSION: Infliximab treatment was associated with a significant increase of both total cholesterol and HDL-cholesterol levels, which correlated with decreasing disease activity. However, this was not accompanied by a favorable effect on the atherogenic index. The favorable effect of infliximab on cardiovascular comorbidity might not be mediated by effects on lipid metabolism, but longterm investigations are needed to confirm this.

Published
2005

236. Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice

Author

Kneepkens, Eva L, primary, Plasencia, Chamaida, additional, Krieckaert, Charlotte LM, additional, Pascual-Salcedo, Dora, additional, van der Kleij, Desiree, additional, Nurmohamed, Michael T, additional, López-Casla, M Teresa, additional, Wieringa, Roeland, additional, Rispens, Theo, additional, and Wolbink, Gertjan, additional

Published
2014
Full Text
View/download PDF

238. Rheumatoid arthritis and metabolic syndrome

Author

Kerekes, György, primary, Nurmohamed, Michael T., additional, González-Gay, Miguel A., additional, Seres, Ildikó, additional, Paragh, György, additional, Kardos, Zsófia, additional, Baráth, Zsuzsa, additional, Tamási, László, additional, Soltész, Pál, additional, and Szekanecz, Zoltán, additional

Published
2014
Full Text
View/download PDF

241. 100. Predictors of Retention with Abatacept in Patients who Have Failed One or More Biologic Agents: Results from the International, Real-World Action Study

Author

Nüßlein, Hubert, primary, Alten, Rieke, additional, Galeazzi, Maurizio, additional, Lorenz, Hannes M., additional, Nurmohamed, Michael T., additional, Bensen, William, additional, Burmester, Gerd R., additional, Peter, Hans-Hartmut, additional, Pavelka, Karel, additional, Chartier, Melanie, additional, Poncet, Coralie, additional, Rauch, Christiane, additional, and Le Bars, Manuela, additional

Published
2014
Full Text
View/download PDF

246. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study

Author

Nüßlein, Hubert G, primary, Alten, Rieke, additional, Galeazzi, Mauro, additional, Lorenz, Hanns-Martin, additional, Boumpas, Dimitrios, additional, Nurmohamed, Michael T, additional, Bensen, William G, additional, Burmester, Gerd R, additional, Peter, Hans-Hartmut, additional, Rainer, Franz, additional, Pavelka, Karel, additional, Chartier, Melanie, additional, Poncet, Coralie, additional, Rauch, Christiane, additional, and Bars, Manuela Le, additional

Published
2014
Full Text
View/download PDF

247. Correction to: Coagulation in gout: is there a link with disease activity?

Author

Vedder, Daisy, Gerritsen, Martijn, Meijers, Joost C. M., and Nurmohamed, Michael T.

Subjects
GOUT, BLOOD coagulation, THROMBIN, FIBRIN fragment D
Abstract

2 Disease activity according the Gout Activity Score is associated with Peak thrombin levels Graph: Fig. 1 Disease activity according the Gout Activity Score is associated with Velocity index Graph: Fig. [Extracted from the article]

Published
2022
Full Text
View/download PDF

248. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up

Author

Kneepkens, Eva L, primary, Wei, James Cheng-Chung, additional, Nurmohamed, Michael T, additional, Yeo, Kai-Jieh, additional, Chen, C Y, additional, van der Horst-Bruinsma, Irene E, additional, van der Kleij, Desiree, additional, Rispens, Theo, additional, Wolbink, Gertjan, additional, and Krieckaert, Charlotte L M, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results